Deucravacitinib Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 6 mg
Reference Brands: Sotyktu (USA/EU)
Category:
Immune Disorder
Deucravacitinib is available in Tablet
and strengths such as 6 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Deucravacitinib is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Deucravacitinib can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Deucravacitinib is an oral targeted therapy used for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It belongs to a newer class of small-molecule medicines known as tyrosine kinase 2 (TYK2) inhibitors. By selectively blocking the TYK2 pathway, deucravacitinib helps regulate immune signaling involved in inflammatory skin disease, leading to reduced plaque formation, redness, and scaling. Its selective mechanism allows more focused immune modulation compared with broader immunosuppressive treatments.
The medicine is taken once daily by mouth, which offers a convenient dosing approach and can support better patient adherence compared to injectable therapies. Clinical studies have shown meaningful improvement in skin clearance and symptom control in many patients with plaque psoriasis. Deucravacitinib is generally prescribed under specialist supervision, with monitoring for potential adverse effects and drug interactions. It is marketed under the brand name Sotyktu and was developed by Bristol Myers Squibb. The product is approved in several major markets for systemic psoriasis treatment.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing